Danish drug company Novo Nordisk has announced a partnership with OpenAI to integrate AI capabilities into its businesses, including drug discovery. Novo Nordisk said it would use OpenAI's technology to analyse large datasets, identify promising drugs, and to improve supply chains and manufacturing. OpenAI will also assist the drug firm in upskilling their workforce and enhancing AI literacy.